4.3 Article

Design, Synthesis, and Biological Evaluation of Novel Pyrrolo [2,3-b] Pyridine Derivatives for Nonalcoholic Fatty Liver Disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Instruments & Instrumentation

Co-delivery of doxorubicin and SIS3 by folate-targeted polymeric micelles for overcoming tumor multidrug resistance

Shuanghu Wang et al.

Summary: The study successfully constructed folate-targeted polymeric micellar carrier for co-delivery of doxorubicin (DOX) and SIS3 (FA/DOX/SIS3 micelles) to sensitize drug-resistant cancer cells, demonstrating superior anti-tumor activity and longer circulation time in blood, preferential accumulation in resistant tumor tissue. The FA/DOX/SIS3 micelles showed promising potential for synergistic treatment of drug-resistant tumors.

DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2022)

Review Endocrinology & Metabolism

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

Chander K. Negi et al.

Summary: NAFLD is the most common form of chronic liver disease worldwide, with current treatment options including dietary restrictions and lifestyle modification. It is closely associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia, with various pharmacological approaches being considered in clinical management.

METABOLISM-CLINICAL AND EXPERIMENTAL (2022)

Article Pharmacology & Pharmacy

SIS3, a good candidate for the reverse of type 2 diabetes mellitus in mice

Dao-Cai Wang et al.

Summary: The TGF-beta signaling pathway is crucial in the development of T2DM, and inhibiting this pathway can protect against obesity and diabetes. SIS3, as a specific inhibitor of Smad3 protein, has shown potential in improving symptoms in a high-fat diet-induced T2DM mouse model.

FUNDAMENTAL & CLINICAL PHARMACOLOGY (2021)

Review Chemistry, Medicinal

Progress and challenges in the prevention and control of nonalcoholic fatty liver disease

Jingjing Cai et al.

MEDICINAL RESEARCH REVIEWS (2019)

Review Gastroenterology & Hepatology

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis

Zobair M. Younossi et al.

JOURNAL OF HEPATOLOGY (2019)

Review Gastroenterology & Hepatology

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Zobair Younossi et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)

Article Biochemistry & Molecular Biology

SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice

Juanjuan Shou et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)

Review Biochemistry & Molecular Biology

Mechanisms of NAFLD development and therapeutic strategies

Scott L. Friedman et al.

NATURE MEDICINE (2018)

Article Gastroenterology & Hepatology

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)

Krzysztof Tomasiewicz et al.

CLINICAL AND EXPERIMENTAL HEPATOLOGY (2018)

Editorial Material Endocrinology & Metabolism

Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs

Niki Katsiki et al.

JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)

Review Nutrition & Dietetics

Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide

Mikhail A. Van Herck et al.

NUTRIENTS (2017)